{"prompt": "['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', '9.', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA (Table 1)', 'Protocol waivers or exemptions are not allowed', 'Immediate safety concerns should be discussed with the sponsor immediately', 'upon occurrence or awareness to determine if the participant should continue or', 'discontinue study treatment.', 'Adherence to the study design requirements, including those specified in the', 'SoA, is essential and required for study conduct.', 'All screening evaluations must be completed and reviewed to confirm that', 'potential participants meet all eligibility criteria. The investigator will maintain a', 'screening log to record details of all participants screened and to confirm', 'eligibility or record reasons for screening failure, as applicable.', \"Procedures conducted as part of the participant's routine clinical management\", '(e.g., blood count) and obtained before signing of ICF may be utilized for', 'screening or baseline purposes provided the procedure met the protocol-', 'specified criteria and was performed within the time frame defined in the SoA.', 'The maximum amount of blood collected from each participant over the', 'duration of the study, including any extra assessments that may be required, will', 'not exceed 500 mL.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical', 'issues with the samples.', '9.1.', 'Efficacy Assessments', '9.1.1.', 'FEV1', '9.1.1.1.', 'Clinic Spirometry', 'Spirometry using FEV1 and FVC measurements (FEV%, and FVC% and FEV1/FVC will', 'be calculated) will be performed in triplicate at time points listed in the SoA (Table 1).', 'Spirometry assessments should be performed in accordance with ATS/ERS guidelines as', 'outlined in the SRM.', '9.1.1.2.', 'Mobile Spirometry', 'Spirometry will also be performed weekly by the participants using a mobile spirometer', 'at home. Details will be outlined in the SRM.', '9.1.2.', 'SGRQ-C', \"The St. George's Respiratory Questionnaire-Chronic Obstructive Pulmonary Disease\", 'specific tool (SGRQ-C) is a disease-specific questionnaire designed to measure the', \"impact of respiratory disease and its treatment on a COPD patient's HRQoL [Meguro,\", '2007]. As well as producing an overall summary score, scores for the individual domains', '37']['2016N293064_03', 'CONFIDENTIAL', '2018N394263_00', '205864', 'of symptoms, activity and impacts are also produced. The SGRQ-C has been used in', 'numerous previous studies of COPD participants and has been translated and validated', 'for use in most major languages. The SGRQ-C is derived from the original SGRQ and', 'produces SGRQ scores equivalent to the original SGRQ instrument [Jones, 1992].', '9.1.3.', 'CAT', 'The COPD Assessment Test is a short and simple patient completed questionnaire which', 'has been developed for use in routine clinical practice to measure the health status of', 'patients with COPD. The CAT is an 8-item questionnaire suitable for completion by all', 'patients diagnosed with COPD [Jones, 2009; Jones, 2012]. When completing the', 'questionnaire, participants rate their experience on a 6-point scale, ranging from 0', '(maximum impairment) to 5 (no impairment) with a scoring range of 0-40. Higher scores', 'indicate greater disease impact.', '9.1.4.', 'COPD Exacerbations', 'An exacerbation of COPD is defined by a worsening of symptoms requiring additional', 'treatment or hospitalization.', 'Details of an exacerbation should be recorded in the exacerbation page of the eCRF.', 'Exacerbations will not be reported according to the standard process for expedited', 'reporting of SAEs to GSK (even though the event may meet the definition of an SAE) as', 'they are considered Disease Related Events (DREs). Only when the event is, in the', \"Investigator's opinion, of greater intensity, or duration than expected for the individual\", 'participant, or the Investigator considers that there is a reasonable possibility that the', 'event is related to study treatment should it be reported as an SAE (See Section 9.2).', '(Pneumonia must be recorded in the AE or SAE section of the eCRF and on the', 'pneumonia page of the eCRF (See Section 9.4.5)).', 'All medications used for the treatment of exacerbations must be recorded in the source', 'documents and the exacerbation page of the eCRF. If necessary the PI or other health', \"care personnel may stop the participant's study treatment temporarily in order to treat the\", 'COPD exacerbation. The reason for temporarily stopping study treatment and duration', 'should be recorded in the eCRF.', 'The date of onset and the date of resolution will be recorded in the source documents and', \"the eCRF based on the Investigator's judgement.\", '9.1.5.', 'Patient Global Rating of Severity and Global Rating of Change in', 'Disease Severity', 'Participants will complete the Global Rating of COPD Severity at randomisation and', 'final study visit or IP Discontinuation Visit. This single global question will ask', 'participants to rate their severity of COPD on a four point scale (mild, moderate, severe,', 'very severe).', 'Participants will complete a Global Rating of Change in COPD (overall disease) question', 'at every visit following randomization (or Early Withdrawal (EW) Visit). Response', '38']\n\n###\n\n", "completion": "END"}